Participating Clinical Centers
Clinical Studies
5406: Mechanism and Response of Thymoglobulin in Patients with Myelodysplastic Syndrome (MDS)
Status: Recruiting
Summary:
Please Note: The Rare Diseases Clinical Research Network will make every effort to enroll all the patients we can, but we cannot make any guarantees that we will be able to enroll everyone in a particular study who wants to participate.
Myelodysplastic syndrome (MDS) is a heterogeneous disease that is characterized by abnormal hematopoiesis that ranges from low-grade MDS to more aggressive stages that often progress to acute leukemia. The primary objective of this study is to estimate the overall clinical response rate to Thymoglobulin as therapy in patients diagnosed with (MDS) and to determine whether presence of expanded T cell clones has predictive power for hematological response.
Target Enrollment:
This study is designed to recruit 14 patients per stratum in phase 1 and then increase to 27 per stratum if there is one responder. Therefore, the total number of patients will range from 28 - 54.
How to Participate:
In order to participate in a study, you must personally contact the study coordinator of any of the participating institutions by phone or by e-mail. Please use the information below to inquire about participation.
- H. Lee Moffitt Cancer Center, Tampa, FL
Justin Williams
813.745.4135
justin.williams@moffitt.org
- Cleveland Clinic Foundation, Cleveland, OH
Susan Sunkle
216.445.2119
sunkles@ccf.org- University of California at Los Angeles, Los Angeles, CA
Lynn Tihopu
310.794.0738
Tihopu@mednet.ucla.edu
Join the Contact Registry: Myelodysplastic Syndromes
